ANAVEX2-73-RS-003 is a Phase 2/3, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 5-17 years of age with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

开始日期2020-07-01

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04575259

/ Completed临床2期

Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001

This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

NCT04314934

/ Completed临床2/3期

Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004

This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.

开始日期2019-10-10

申办/合作机构

Anavex Life Sciences Corp.

[+2]

100 项与 Blarcamesine 相关的临床结果

登录后查看更多信息

100 项与 Blarcamesine 相关的转化医学

登录后查看更多信息

100 项与 Blarcamesine 相关的专利（医药）

登录后查看更多信息

项与 Blarcamesine 相关的文献（医药）

2025-03-01·European Journal of Medicinal Chemistry

Progress in the study of anti-Alzheimer's disease activity of pyrimidine-containing bioactive molecules

Review

作者: Chui, Rui-Hao ; Ma, Li-Ying ; Zhang, Qi ; Zhang, Qian ; Li, Bing-Qian ; Zhang, Di ; Liu, Yu-Lin ; Zhang, Lin-Lin

Pyrimidines are aromatic, heterocyclic organic compounds characterized by a six-membered ring that contains four carbon atoms and two nitrogen atoms. They have been reported to exhibit a variety of biological activities such as antifungal, antiviral, and anti-Parkinsonian effects. Recently, there has been an increased focus on their potential anti-Alzheimer's properties. Several pyrimidine-based drugs and their analogs are currently undergoing various phases of clinical trials, indicating pyrimidine as a promising chemical structure for drug development. Notably, modifications to the pyrimidine structure significantly influence their activity against Alzheimer's disease. For instance, the introduction of heteroatoms into the pyrimidine ring or alternations in the length of the linkage region have been shown to enhance therapeutic efficacy. This review provides a comprehensive overview of pyrimidine derivatives as potential therapeutics for Alzheimer's disease, with a focus on structure-activity relationship (SAR) studies, design strategies, and binding mechanisms. These insights could pave the way for the development of more effective anti-Alzheimer's medications.

2025-01-01·The Journal of Prevention of Alzheimer's Disease

Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial

Article

作者: Jubault, Thomas ; Thompson, Alex ; Kurrle, Susan ; Frölich, Lutz ; Peters, Oliver ; Short, Cathy ; MacSweeney, J Emer ; Brew, Bruce J ; Sharif, Saif ; Connell, Sandra ; Grimmer, Timo ; Bharadwaj, Sneha ; Woodward, Michael ; Dautzenberg, Paul Lj ; Krishna, Vivek ; Kaufmann, Walter E ; Oschmann, Patrick ; Barton, David ; Guizard, Nicolas ; Chertkow, Howard ; Brittain, Rodney ; Wiltfang, Jens ; Pasternak, Stephen ; Cohen, Sharon ; Perry, Richard ; Tucker, Amanda ; Villa, Luca M ; Evans, Craig ; Hsiung, Ging-Yuek Robin ; Asher, Aliya ; Mannering, Nicholas ; Tacik, Pawel ; Brodtmann, Amy ; Lynch, Jennifer ; Kalafatis, Chris ; Rutgers, Sterre Malou ; Sabbagh, Marwan N ; Drysdale, Peter ; Gordon, Elizabeth ; Lai, Rosalyn ; Mander, Alastair ; Macfarlane, Stephen ; Smith, Eric ; Missling, Christopher U ; Henri-Bhargava, Alexandre ; Ingram, Jennifer ; Frank, Andrew ; Sturm, Jonathan ; Chezem, William R ; Prins, Niels ; Morris, Philip ; Munisamy, Malathy ; O'Brien, Terence J ; Pearson, Stephen ; Jin, Kun ; Tartaglia, Carmela ; Teo, Ken ; Lewis, Simon J G ; Bhatt, Neel ; Grunfeld, Jennifer

BACKGROUNDThere are no approved oral disease-modifying treatments for Alzheimer's disease (AD).OBJECTIVESThe objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.DESIGNANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.SETTINGMulticenter - 52 medical research centers/hospitals in 5 countries.INTERVENTION508 participants with early AD (Stage 3) were randomized to receive either blarcamesine (n = 338) in medium dose group 30 mg or in high dose group 50 mg or placebo (n = 170) oral capsules once daily for 48 weeks. Participants in these groups were offered to enroll into the open-label-extension study ATTENTION-AD, which completed June 2024, ClinicalTrials.gov Identifier NCT04314934.MEASUREMENTSThe co-primary cognitive and functional outcomes were assessed as change in ADAS-Cog13 and ADCS-ADL from baseline to 48 weeks. The outcomes include the secondary outcome CDR-SB and biomarkers from the A/T/N spectrum, plasma Aβ42/40-ratio and global brain volume changes measured by MRI. All clinical endpoints were analyzed using mixed model for repeated measures (MMRM), plasma biomarker measurements were analyzed by Welch's t-test, and volumetric MRI scans were analyzed by general linear model.RESULTSAmong 462 randomized participants in the intent-to-treat population (mean age, 73.7 years; 225 [48.7%] women), 338 (73.2%) completed the trial. The co-primary outcome was met under the multiplicity control rule, since the differences in the least-squares mean (LSM) change from baseline to 48 weeks between the prespecified blarcamesine and placebo groups for ADAS-Cog13 was significant at a level of P < 0.025 and for CDR-SB was significant at a level of P < 0.025, while ADCS-ADL did not reach significance at Week 48 (ADAS-Cog13 difference of -2.027 [95% CI -3.522 to -0.533]; P = 0.008; CDR-SB difference of -0.483 [95% CI -0.853 to -0.114]; P = 0.010; ADCS-ADL difference of 0.775 [95%CI -0.874 to 2.423]; P = 0.357). Plasma Aβ42/40-ratio increased significantly with blarcamesine group vs. placebo, (P = 0.048) and whole brain volume loss was significantly decreased (P = 0.002). Participants in the full safety population with ≥1 serious treatment-emergent adverse events (TEAEs) occurred in 56 participants (16.7%) in the blarcamesine and 17 (10.1%) in the placebo group. Common TEAEs included dizziness, which was transient and mostly mild to moderate in severity. One death in the blarcamesine group and 1 in the placebo group were both not considered treatment related.CONCLUSIONSBlarcamesine, demonstrating a safety profile with no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the individual 30 mg (by 34.6%) and 50 mg (by 38.5%) blarcamesine groups vs. placebo on the prespecified primary cognitive endpoint ADAS-Cog13. The prespecified secondary endpoint CDR-SB, which is used as the sole primary endpoint in recent successful AD drug submissions, is significantly improved at Week 48 with blarcamesine relative to placebo. The findings are supported by biomarkers from the A/T/N spectrum, including plasma Aβ42/40-ratio and reduction of whole brain atrophy. Additionally, the prespecified SIGMAR1 gene variant subgroup analysis confirmed beneficial clinical effect of blarcamesine group through upstream SIGMAR1 activation - subjects with the common SIGMAR1 wild-type gene (excluding carriers of the mutated SIGMAR1 rs1800866 variant) experienced an even greater significant clinical benefit with slowed clinical progression by 49.8% at 48 weeks on the prespecified primary cognitive endpoint ADAS-Cog13. Oral once daily blarcamesine could represent a novel treatment in early AD and be complementary or alternative to anti-beta amyloid drugs.

2024-11-01·CNS Drugs

Rett Syndrome: The Emerging Landscape of Treatment Strategies

Review

作者: Percy, Alan K. ; Neul, Jeffrey L. ; Percy, Alan K ; Neul, Jeffrey L ; Ananth, Amitha

Rett syndrome (RTT) has enjoyed remarkable progress in achieving specific therapies. RTT, a unique neurodevelopmental disorder first described in 1966, progressed slowly until the landmark paper of Hagberg and colleagues in 1983. Thereafter, rapid advances were achieved including the development of specific diagnostic criteria and the active search for a genetic etiology, resulting 16 years later in identification of variants in the methyl-CpG-binding protein (MECP2) gene located at Xq28. Shortly thereafter, the NIH Office of Rare Diseases funded the RTT Natural History Study (NHS) in 2003, initiating the acquisition of natural history data on clinical features from a large population of individuals with RTT. This information was essential for advancement of clinical trials to provide specific therapies for this disorder. In the process, the International Rett Syndrome Association (IRSA) was formed (now the International Rett Syndrome Foundation-IRSF), which participated directly in encouraging and expanding enrollment in the NHS and, subsequently, in developing the SCOUT program to facilitate testing of potential therapeutic agents in a mouse model of RTT. The overall objective was to review clinical characteristics developed from the NHS and to discuss the status of specific therapies for this progressive neurodevelopmental disorder. The NHS study provided critical information on RTT: growth, anthropometrics, longevity, key comorbidities including epilepsy, breath abnormalities, gastroesophageal dysfunction, scoliosis and other orthopedic issues, puberty, behavior and anxiety, and progressive motor deterioration including the appearance of parkinsonian features. Phenotype-genotype correlations were noted including the role of X chromosome inactivation. Development of clinical severity and quality of life measures also proved critical for subsequent clinical trials. Further, development of biochemical and neurophysiologic biomarkers offered further endpoints for clinical trials. Initial clinical trials prior to the NHS were ineffective, but advances resulting from the NHS and other studies worldwide promoted significant interest from pharmaceutical firms resulting in several clinical trials. While some of these have been unrewarding such as sarizotan, others have been quite promising including the approval of trofinetide by the FDA in 2023 as the first agent available for specific treatment of RTT. Blarcamesine has been trialed in phase 3 trials, 14 agents have been studied in phase 2 trials, and 7 agents are being evaluated in preclinical/translational studies. A landmark study in 2007 by Guy et al. demonstrated that activation of a normal MECP2 gene in a null mouse model resulted in significant improvement. Gene replacement therapy has advanced through translational studies to two current phase 1/2 clinical trials (Taysha102 and Neurogene-401). Additional genetic therapies are also under study including gene editing, RNA editing, and X-chromosome reactivation. Taken together, progress in understanding and treating RTT over the past 40 years has been remarkable. This suggests that further advances can be expected.

110

项与 Blarcamesine 相关的新闻（医药）

2025-02-12

·anavex.com

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK – February 12, 2025 Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its first quarter of fiscal 2025. “We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer’s disease with convenient oral dosing with potential clinical meaningful benefit,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “We are excited to potentially making a difference for individuals suffering from Alzheimer’s disease, by presenting a scalable treatment alternative alongside the ease of oral administration.” Recent Highlights: On January 27, 2025, Anavex announced it was issued a new composition of matter U.S. Patent, expected to remain in force at least until July 2039, entitled “A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF” from the United States Patent and Trademark Office (USPTO). This new patent claims crystalline forms of the dihydrogen phosphate salt of ANAVEX®2-73 (blarcamesine), freebase, transdermal patches and enteric coated oral dosage forms including the same for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and other disorders. On January 15, 2025, Anavex announced that The Journal of Prevention of Alzheimer’s Disease (JPAD)  published peer-reviewed detailed results from the Phase IIb/III study evaluating oral blarcamesine (ANAVEX®2-73) for the treatment of early Alzheimer’s Disease (AD). Once daily oral blarcamesine, demonstrating a safety profile with no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the prespecified SIGMAR1 wild-type gene group by 49.8% at 48 weeks on the prespecified primary cognitive endpoint ADAS-Cog13, respectively. On January 13, 2025, Anavex provided topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial. The data demonstrated that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) significantly reduced clinical decline showing continued clinically and meaningful benefit for early Alzheimer’s disease patients. On January 27, 2025, Anavex announced it was issued a new composition of matter U.S. Patent, expected to remain in force at least until July 2039, entitled “A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF” from the United States Patent and Trademark Office (USPTO). This new patent claims crystalline forms of the dihydrogen phosphate salt of ANAVEX®2-73 (blarcamesine), freebase, transdermal patches and enteric coated oral dosage forms including the same for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and other disorders. On January 15, 2025, Anavex announced that The Journal of Prevention of Alzheimer’s Disease (JPAD)  published peer-reviewed detailed results from the Phase IIb/III study evaluating oral blarcamesine (ANAVEX®2-73) for the treatment of early Alzheimer’s Disease (AD). Once daily oral blarcamesine, demonstrating a safety profile with no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the prespecified SIGMAR1 wild-type gene group by 49.8% at 48 weeks on the prespecified primary cognitive endpoint ADAS-Cog13, respectively. On January 13, 2025, Anavex provided topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial. The data demonstrated that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) significantly reduced clinical decline showing continued clinically and meaningful benefit for early Alzheimer’s disease patients. Financial Highlights: Cash and cash equivalents of $120.8 million at December 31, 2024 compared to $132.2 million at September 30, 2024. As of quarter end, the Company anticipates at current cash utilization rates and ranges, a runway of approximately 4 years. General and administrative expenses for the first quarter of $3.1 million compared to $2.7 million for the comparable first quarter of fiscal 2024. Research and development expenses for the first quarter of $10.4 million compared to $8.7 million for the comparable first quarter of fiscal 2024. Net loss for the first quarter of $12.1 million, or $0.14 per share, compared to a net loss of $8.6 million, or $0.11 per share for the comparable first quarter of fiscal 2024. Cash and cash equivalents of $120.8 million at December 31, 2024 compared to $132.2 million at September 30, 2024. As of quarter end, the Company anticipates at current cash utilization rates and ranges, a runway of approximately 4 years. General and administrative expenses for the first quarter of $3.1 million compared to $2.7 million for the comparable first quarter of fiscal 2024. Research and development expenses for the first quarter of $10.4 million compared to $8.7 million for the comparable first quarter of fiscal 2024. Net loss for the first quarter of $12.1 million, or $0.14 per share, compared to a net loss of $8.6 million, or $0.11 per share for the comparable first quarter of fiscal 2024. The financial information for the quarter ended December 31, 2024, should be read in conjunction with the Company’s consolidated financial statements, which will appear on EDGAR, www.sec.gov and will be available on the Anavex website at www.anavex.com. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Andrew J. Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com

临床结果临床3期财报临床2期

2025-02-01

·GlobeNewswire-Health Care

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Jan. 27, 2025 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent No. 12,180,174 entitled “A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF” from the United States Patent and Trademark Office (USPTO) for its U.S. Patent Application Serial Number USSN: 17/978,818. This new patent claims crystalline forms of the dihydrogen phosphate salt of ANAVEX®2-73 (blarcamesine), freebase, transdermal patches and enteric coated oral dosage forms including the same for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and other disorders. Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) patent portfolio, which includes several U.S. Patents, including U.S. Patent Nos. 10,413,519; 10,966,952; 11,661,405; and 11,498,908. “The issuance of this U.S. Patent again showcases our expertise in identifying and pursuing novel therapeutic forms and formulations that are rooted in science,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. He further added: “We believe the unique properties of the dihydrogen phosphate crystals make it possible in addition to convenient once daily oral dosing to also deliver the active (ANAVEX®2-73 freebase) in transdermal patches, which could simplify further the administration and boost patients’ compliance. As such, we believe that the addition of the dihydrogen phosphate crystals to our platform could greatly benefit the patients at large.” Crystal polymorphism is a unique phenomenon related to chiral compounds, wherein the compounds may crystallize into different crystal structures or crystal forms under different conditions and/or processes. Specifically for pharmaceuticals, polymorphic forms of drug substances ‘exist in different crystalline forms which differ in their physical properties’.1 These property differences may result in direct medical implications, such as ease of formulation, increased efficacy, and reduced side effects. For example, the widely used analgesic drug, acetaminophen has three polymorphic forms, I, II, and III, among which only Form I is made into commercial dosage forms as the other two forms are either meta-stable or unstable.2 Nonetheless, uncovering an optimal crystal form is NOT an easy or straightforward task, because there are so many variables and possibilities involved, and chance of success lies heavily on the researcher’s experience and insights into the compounds in question. Both ANAVEX®2-73 (blarcamesine) and ANAVEX®19-144 have the potential to form different crystal forms. Through its deep understanding and abundance experience with these two compounds, Anavex was successful in discovering crystal forms of ANAVEX®2-73 (blarcamesine) and ANAVEX®19-144 that have advantageous physiochemical and/or pharmacological properties. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. 1 ICH HARMONISED TRIPARTITE GUIDELINE, SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES Q6A, Current Step 4 version dated 6 October 1999, page 8. 2 Lee E.H., “A practical guide to pharmaceutical polymorph screening & selection,” Asian Journal of Pharmaceutical Sciences, Vol 9, Issue 4, August 2014, Pages 163-175. The content above comes from the network. if any infringement, please contact us to modify.

临床结果

2025-01-17

·FiercePharma

Analysts tip Eisai, Biogen and Lilly to drive eightfold explosion in Alzheimer's market value

Leqembi and Kisunla are key building blocks of GlobalData’s prediction. GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase eightfold in a decade as therapies address unmet medical need.The analysts valued the Alzheimer’s market across the U.S., France, Germany, Italy, Spain, U.K., Japan and China at a combined $2.4 billion in 2023. That figure says more about the dearth of treatment options than the needs of patients: Western populations are aging, and an estimated 4% of people aged 65 years and older in the U.S. alone have a dementia diagnosis, according (PDF) to the Centers for Disease Control and Prevention. The constraint has been a lack of good drugs to treat those patients.Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for Alzheimer’s. Philippa Salter, managing neurology analyst at GlobalData, said in a statement that the companies will turn their early-mover advantage into market leadership. Salter is tipping sales of Leqembi and Kisunla to reach $3.6 billion and $3.8 billion, respectively, by 2033.The forecast makes Leqembi and Kisunla key building blocks of GlobalData’s prediction that the overall Alzheimer’s business across the eight major markets will grow to $19.3 billion by 2033. Salter identified Anavex Life Sciences’ ANAVEX2-73, TauRx Therapeutics’ LMTX and Novo Nordisk’s semaglutide as other molecules that could contribute to the growth of the market in the coming years.For its part, Novo’s assessment of semaglutide, the active ingredient in Ozempic and Wegovy, in Alzheimer’s is built on a series of studies that have linked GLP-1 analogs to improved outcomes in the neurodegenerative disease. None of the studies prove the mechanism works in Alzheimer’s, but the signs were sufficiently encouraging to persuade Novo to run a trial that could boost the already rocket-propelled GLP-1 market. That trio of molecules stands out in the late-stage pipeline because of their novel mechanisms, convenient oral administration and improved safety profiles compared to Leqembi and Kisunla, according to GlobalData. The fact that Leqembi and Kisunla are “only considered moderately effective” leaves room for better drugs, the analysts said, and spurs ongoing work toward the end goal of preventing disease.“Key opinion leaders interviewed by GlobalData did not believe there will ever be one product that can cure AD. Rather, they consistently expressed that the future of AD treatment will entail the combinatory use of preventative, symptomatic and disease-modifying products,” Salter said. “Despite the significant anticipated growth for the AD market, many opportunities remain for developers.”

100 项与 Blarcamesine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11383	Blarcamesine	-	DB05592

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	申请上市	欧盟	Anavex Life Sciences Corp.	2023-11-20
Rett综合征	临床3期	英国	Anavex Life Sciences Corp.	2019-05-06
Rett综合征	临床3期	澳大利亚	Anavex Life Sciences Corp.	2019-05-06
帕金森病所致痴呆	临床3期	西班牙	Anavex Life Sciences Corp.	2018-07-09
帕金森病所致痴呆	临床3期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床3期	西班牙	Anavex Life Sciences Corp.	2018-07-09
帕金森病	临床3期	澳大利亚	Anavex Life Sciences Corp.	2018-07-09
脆性X综合征	临床3期	美国	Anavex Life Sciences Corp.	-
天使综合征	临床1期	-	Anavex Life Sciences Corp.	-
婴儿痉挛	临床1期	-	Anavex Life Sciences Corp.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04314934 (ATTENTION-AD, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	blarcamesine (early start treatment)	(淵鹽顧鹹獵夢醖遞艱憲) = from previously 25.2% in the ANAVEX®2-73-AD-004 trial to 9.6% in the ATTENTION-AD trial. 齋壓蓋鹽獵構夢遞鑰醖 (憲餘簾觸膚衊鹹築鏇蓋 ) 更多	积极	2025-01-13
				blarcamesine (late start treatment)
NCT04314934 (GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	-	Blarcamesine 50 mg	(鬱壓糧鹽醖餘簾淵鏇願) = 獵齋鹽網窪顧築鏇窪壓鑰壓膚鹹鑰獵鑰廠蓋製 (網製鏇夢窪築製願選繭 ) 更多	积极	2024-07-28
				Blarcamesine 30 mg	(鬱壓糧鹽醖餘簾淵鏇願) = 網糧衊網壓衊鑰艱範糧鑰壓膚鹹鑰獵鑰廠蓋製 (網製鏇夢窪築製願選繭 ) 更多
NCT04304482 (EXCELLENCE, GlobeNewswire) 人工标引	临床2/3期	Rett综合征	92	ANAVEX2-73	(鬱願齋餘夢窪糧選選艱) = 醖網糧鹹膚鏇蓋顧蓋襯構鏇願鑰鹹醖積鑰膚壓 (廠鏇簾糧網鏇繭繭製鏇, 2.150) 更多	积极	2024-01-02
				Placebo	(鬱願齋餘夢窪糧選選艱) = 醖構願願艱簾積齋鬱願構鏇願鑰鹹醖積鑰膚壓 (廠鏇簾糧網鏇繭繭製鏇, 2.537) 更多
NCT03790709 (Corporate Publications) 人工标引	临床2/3期	阿尔茨海默症	508	ANAVEX2-73	(鑰範齋範壓夢願願簾獵): Difference = -1.783 (95% CI, −3.314 ~ −0.251), P-Value = 0.0226 达到更多	积极	2023-09-14
				Placebo
NCT03790709 (ANAVEX2-73-AD-004, GlobeNewswire) 人工标引	临床2/3期	阿尔茨海默症	509	Blarcamesine	(壓觸艱獵鏇積餘鹹顧艱): OR = 1.84, P-Value = 0.015 更多	积极	2022-12-01
				Placebo
NCT03758924 (Biospace) 人工标引	临床2期	Rett综合征 SIGMAR1	-	Blarcamesine	(廠構選構鏇衊願醖衊鬱) = 齋衊遞製願鹹糧齋鑰鏇積鑰窪鏇積鹹衊積鹹構 (鬱簾壓鹽網襯膚廠膚醖 ) 更多	积极	2021-06-21
				Placebo	-
CTAD2015	临床2期	-	-	ANAVEX 2-73	蓋衊積製餘壓鹹糧鹽壓(鏇鬱衊糧願鬱積鬱鹽願) = The average Cogstate test improved across the test batteries 鹽網憲襯鏇淵衊鹽餘積 (夢鏇簾簾壓齋鏇網壓網 ) 更多	积极	2015-11-04